Preferences, Adherence, and Satisfaction: Three Years of Treatment Experiences of People with Multiple Sclerosis
Olaf Hoffmann,Friedemann Paul,Rocco Haase,Raimar Kern,Tjalf Ziemssen
DOI: https://doi.org/10.2147/ppa.s452849
2024-02-27
Patient Preference and Adherence
Abstract:Olaf Hoffmann, 1– 3 Friedemann Paul, 3,4 Rocco Haase, 5 Raimar Kern, 6 Tjalf Ziemssen 5 1 Department of Neurology, Alexianer St. Josefs-Krankenhaus Potsdam, Potsdam, Germany; 2 Medizinische Hochschule Brandenburg Theodor Fontane, Neuruppin, Germany; 3 Experimental and Clinical Research Center, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität Zu Berlin, Berlin, Germany; 4 Max Delbrueck Center for Molecular Medicine, Berlin, Germany; 5 Center of Clinical Neuroscience, Department of Neurology, University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany; 6 MedicalSyn GmbH, Stuttgart, Germany Correspondence: Olaf Hoffmann, Alexianer St. Josefs-Krankenhaus Potsdam, Department of Neurology, Allee nach Sanssouci 7, 14471 Potsdam, Brandenburg, Germany, Tel +49 331 9682 6000, Fax +49 331 9682 6009, Email Background: To reduce the risk of long-term disability in people with Multiple Sclerosis (pwMS), an increasing number of disease-modifying immune therapies (DMT) are available, involving diverse mechanisms of action, levels of efficacy, treatment risks, and tolerability aspects. Including patient preferences and expectations in shared decision-making may improve treatment satisfaction, adherence, and persistence. Purpose: To investigate long-term alignment of individual preferences and expectations of pwMS with their actual DMT and its effect on treatment satisfaction, health-related quality of life (HRQoL), adherence, and treatment discontinuation. Methods: A total of 401 pwMS beginning a new DMT were enrolled from 2015 to 2018 in a non-interventional study at three German MS centres. Patient preferences regarding DMT, TSQM-9, SF36, and self-reported adherence as well as relapses and EDSS were recorded at baseline and every 3 to 6 months for up to 3 years. Results: Efficacy and tolerability were the highest-ranking preferences at baseline. Actual selection of DMT corresponded more closely to safety than efficacy, tolerability, or convenience preferences. Participants reported excellent adherence throughout the study. DMT persistence was 69.0%, with earlier discontinuation for injectable vs oral or infusion therapies. Breakthrough disease, rather than patient-reported outcomes, was the main driver of DMT discontinuation. For all routes of administration, global treatment satisfaction increased over time despite lower satisfaction with convenience. Several patterns of changing preferences were observed. Conclusion: This study provides insight into the interaction of DMT preferences of pwMS with their actual treatment experience. Treatment decisions should be aligned with long-term expectations of pwMS to promote continuous adherence. Keywords: multiple sclerosis, treatment adherence and compliance, treatment discontinuation, patient preference, health-related quality of life Multiple sclerosis (MS) is the most common autoimmune demyelinating disorder of the central nervous system, affecting 2.8 million worldwide. 1 In most people with MS (pwMS), the disease is initially characterised by recurring relapses, separated by phases of complete or partial remission of symptoms (relapsing-remitting MS, RRMS), whereas about 10% experience progressive deterioration from onset (primary progressive MS, PPMS). 2 Individuals affected by RRMS, typically young adults, are at risk of accumulating neurological deficits and severe disability from clinical relapses and neurodegeneration. 3,4 Physical, cognitive, and psychiatric symptoms, as well as effects on everyday life develop in a highly individual manner. In the absence of a cure, disease-modifying therapy (DMT) aims to reduce harmful adaptive immune responses by modulating or depleting pro-inflammatory lymphocytes subsets or restricting their access to the CNS. 5 Effective control of inflammatory disease activity, ie, preventing relapses and formation of new lesions on MRI, slows the accumulation of disability and reduces the risk of transitioning from RRMS to a secondary chronic progressive course (SPMS) that is much less amenable to DMT. 6 Over the past decade, immunomodulatory therapy options for pwMS have expanded significantly, involving different routes of application (oral, infusion, subcutaneous or intramuscular injection) and frequencies of treatment. 5 Diverse mechanisms of action translate into moderately vs highly efficient therapies (MET, HET) as well as drug-specific safety and tolerability aspects. 5,7 In parallel, individual prognostication has improved, considering personal co-factors as well as MRI findings and liquid b -Abstract Truncated-
medicine, general & internal